How Phages Could Hijack Vaccine Immunity to Target and Destroy Cancer Cells

Transmission electron micrograph of E. coli cells infected with phage (green dots)

Transmission Electron Micrograph of E. coli Infected with Phage (Green Dots)

M. Mader/Department of Microbiology, Biozentrum/Science Photo Library

A groundbreaking study reveals that bacteriophages, viruses that target bacteria, can help in eliminating cancer cells by reorienting the immune response established through vaccination. In experiments involving mice vaccinated against malaria, a harmless phage was utilized to target and eradicate tumors, achieving success in nearly 44% of the subjects.

Immunotherapy has revolutionized cancer treatments, yet many patients do not reap its benefits due to the challenge of getting the immune system to identify tumors as threats. To address this,
Amin Hajitou and his team from Imperial College London investigated phages that specifically infect
Escherichia coli. These phages attach to bacteria, inject their genetic material, and replicate, thereby destroying the bacterial cells.

The research team engineered the phages to specifically target proteins known as αvβ3 and αvβ5 integrins, which are prevalent in tumor cells but scarce in healthy cells. Additionally, they customized the phages to produce malaria-specific antigens—signals that prompt the immune system to recognize them as foreign invaders. “Phages function as targeted delivery vehicles,” explains Hajitou.

The efficacy of this approach was tested on 60 mice with subcutaneous tumors. Among them, 15 mice received a malaria vaccine followed by injections of engineered phages at two-week intervals. The control group consisted of 15 mice each receiving no treatment, the malaria vaccine only, or the engineered phage exclusively.

The results revealed that tumors disappeared in 44% of the treated mice, with no recurrence observed a year post-study. Although the treated mice exhibited longer lifespans compared to controls, a survival advantage was not significantly noted.

According to
David Withers at Oxford University, “These engineered viruses can target and infect tumor cells systemically.” This strategy marks a significant advancement over current methods of manipulating tumors, such as oncolytic viruses, which necessitate direct injections at cancer sites—an impractical method especially for metastatic diseases.

By fine-tuning the phage’s antigen-producing capabilities, this innovative approach could also extend its effectiveness to individuals vaccinated against other infectious diseases like seasonal influenza and COVID-19, showcasing the versatility of this method. Hajitou asserts, “More potent vaccines than malaria are likely to yield even greater results.” The aim is to leverage existing immune memory without being limited to malaria-specific responses.

The research team is currently engaging with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to explore the possibility of commencing early-stage human trials next year.

Topics:

Source: www.newscientist.com

Phage Therapy: Harnessing Viral Power to Enhance Vaccine Immunity and Target Cancer Cells

Transmission electron micrograph of E. coli cells infected with phage (green dots)

Transmission Electron Micrograph Reveals E. coli Cells Infected by Phage (Green Dots)

M. Mader/Department of Microbiology, Biozentrum/Science Photo Library

A groundbreaking study reveals that a bacteria-killing virus can selectively destroy cancer cells in mice. By harnessing the immunity generated from vaccination, researchers redirected the immune response to effectively target and eradicate tumors. In trials, nearly 50% of vaccinated mice infected with a harmless phage demonstrated tumor disappearance.

Immunotherapy has revolutionized cancer treatment, but many still struggle to benefit due to challenges in immune system recognition of tumors. The latest research aims to enhance this recognition.

Researchers led by Amin Hajitou at Imperial College London investigated phages that infect Escherichia coli. Upon infecting the bacteria, these phages inject genetic material, reprogramming the bacterial machinery to generate numerous new phages that effectively eradicate these pathogens.

To improve targeting, the team genetically engineered the phages to recognize proteins called αvβ3 and αvβ5 integrins, which are prevalent in many tumor cells but are scarce in healthy tissues. Additionally, they modified the phage’s genetic payload to include malaria-specific antigens to stimulate a robust immune response. “Phages serve as precision delivery vehicles for our interventions,” states Hajitou.

The researchers conducted tests on 60 mice with tumors positioned under the skin. A subset received a malaria vaccine, followed by phage injections in the tail over two weeks. Control groups included those receiving no treatment, only the vaccine, or only the engineered phage.

Results showed that tumors vanished in 44% of treated mice, and notably, these tumors did not recur a year post-study. Additionally, treated mice exhibited increased lifespans compared to their untreated counterparts, though no significant survival advantage was observed.

“This innovative approach allows engineered viruses to systematically target tumor cells,” remarks David Withers from Oxford University. “This capability markedly enhances current strategies for manipulating tumors, such as using oncolytic viruses, which are limited by the need for direct administration into cancer sites.”

With further adjustments to the phage’s antigen-producing capabilities, the technique may also apply to humans vaccinated against diseases like seasonal influenza and COVID-19. “Utilizing more effective vaccines than malaria could amplify our results,” Hajitou explains. “This strategy leverages pre-existing immune memory and is not confined to malaria alone.”

The research team is currently in discussions with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate early-stage human trials as soon as next year.

Topics:

Source: www.newscientist.com

The Impact of High Blood Pressure on Brain Immunity




NINDS Research on High Blood Pressure and Cognitive Decline

NINDS Research on High Blood Pressure and Cognitive Decline

by National Institute of Neurological Disorders and Stroke (NINDS) December 14, 2023

NIH-funded researchers have found that high blood pressure leads to an increase in interleukin-17 in the brain, which activates immune cells and causes cognitive decline. The discovery, made using a mouse model, points to the possibility of new treatments by targeting T cells in the brain’s protective membranes. Credit: SciTechDaily.com

An NIH-funded study in mice suggests a potential new target for treating hypertension. Research supported by National Institutes of Health The findings suggest that a response of immune system cells within the protective membrane that surrounds the brain may contribute to the cognitive decline that can occur in people with chronic hypertension. This discovery is natural neuroscience, may shed light on new ways to counter the effects of high blood pressure on cognition. This study was funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the NIH. “Understanding the role of immune signaling in cognitive decline is critical,” said Dr. Roderick Corriveau, NINDS program director. “These findings provide insight into how signaling from the immune system contributes to the symptoms of cognitive decline that ultimately lead to the diagnosis of dementia.”

Global impact of hypertension and its impact on cognition

High blood pressure affects more than 1 billion people worldwide and can cause cognitive decline not only when a stroke occurs, but even when a person with high blood pressure does not have a stroke. However, efforts to control cognitive decline in people who have not had a stroke with blood pressure-lowering treatments have shown mixed results. The results of this mouse study suggest that under conditions that mimic common hypertension, immune cells around and within the brain become abnormally activated, and that this activation leads to impaired brain function. Fluorescent staining reveals an extensive vascular network of the dura mater. These blood vessels contain her T cells, which are activated in mouse models of chronic hypertension, causing a condition that can lead to dementia-like symptoms. Credit: Iadecola Lab

Research Insights: Mouse models of hypertension

Researchers led by Costantino Iadecola, MD, director and director of the Feil Family Brain and Mind Institute in New York City, used a mouse model of hypertension to investigate interleukin-17 (IL-17). It was discovered that the levels of A chemical normally released in the body, cerebrospinal fluid, and brain to activate the immune system. Previously, Dr. Iadekola’s team showed that a high-salt diet increases IL-17 in the intestine, followed by cognitive impairment. These new findings further deepen the story by showing that IL-17 is acting within the brain itself. It is also worth noting that these experiments used a different mouse model called the DOCA salt model, which more closely mimics common hypertension in humans. “This is the most realistic model of hypertension that we have at this time,” Dr. Iadecola said. “DOCA mice simulate low-renin hypertension, a type of hypertension that is common in people, especially black Americans.”

Role of IL-17 and brain macrophages

Further research has shown that when IL-17 enters the brain, it activates immune cells known as macrophages, which are responsible for activating inflammation and fighting infections. A series of experiments showed that both mice with brain macrophage deletion of IL-17 receptors and mice with brain macrophage depletion showed no effect of hypertension on cognitive function, and therefore these macrophages were not associated with the observed cognitive function. It was confirmed that this is important for the reduction of Functioning despite other hypertension symptoms. Researchers were still looking for a source of IL-17 that acts on brain macrophages. Based on previous studies, the researchers’ initial hypothesis was that the gut releases IL-17, which travels to the brain through the bloodstream. Once there, a reaction is triggered that damages the ability of the brain’s blood vessels to respond appropriately to increased brain activity. However, blocking the ability of cerebral blood vessels to respond to IL-17 only partially reversed the cognitive impairment, suggesting that another source of IL-17 is acting on the brain. Uncovering IL-17 pathways and protective barriers One clue suggests that one layer of the brain’s protective layer, known as the dura mater, contains immune T cells that secrete IL-17 and may influence mouse behavior. taken from other recent studies. Using special mice whose cells glow fluorescent green when they make IL-17, the researchers found that high blood pressure increases IL-17 in the dura mater, which is then released into the tissues. Normally, a barrier exists within the brain’s protective covering called the meninges to prevent unwanted spillage into the brain. However, in mice with experimentally induced hypertension, this barrier appears to be disrupted, allowing IL-17 to enter the cerebrospinal fluid. Two additional experiments helped confirm this hypothesis. First, drugs were used to block the migration of her T cells from the lymph nodes to the meninges. Second, antibodies were used to block the activity of her T cells within the meninges. In both cases, the hypertensive mice recovered cognitive function, suggesting that targeting hyperactive T cells may be a new therapeutic approach worth exploring. “Taken together, our data suggest that hypertension causes two distinct effects,” Dr. Iadecola said. “One is that IL-17 has an effect on blood vessels, but this seems to be relatively minor. The more prominent central effect is that IL-17 releases IL-17, which has a direct effect on immune cells in the brain. It is caused by cells in the meninges. These immune cells, activated by signaling from the meninges, affect the brain in a way that ultimately causes cognitive impairment.”

Future Research Directions

Dr. Iadekola and his team are now trying to connect the dots between activation of immune cells in the meninges and cognitive decline. Previous works by the group The researchers suggested a link between a high-salt diet, which suppresses the production of the chemical nitric oxide in brain blood vessels, and the resulting accumulation of tau, a toxic protein that forms clumps within affected neurons. Alzheimer’s disease disease. The findings also indicate suppression of nitric oxide production in cerebral blood vessels, and whether this also leads to increased tau production is currently being investigated.

Reference: “Meningeal interleukin-17-producing T cells mediate cognitive impairment in a mouse model of salt-sensitive hypertension” Monica M. Santisteban, Samantha Schaeffer, Antoine Anfray, Giuseppe Faraco, David Brea, Gang Wang, Melissa J. Sobanko , Rose Sciortino, Gianfranco Rachumi, Ali Wiseman, Rybaik Park, Joseph Anraser, Costantino Iadecola, December 4, 2023, natural neuroscience.DOI: 10.1038/s41593-023-01497-z of NINDS’ Mind Your Risks® Campaign This paper highlights the relationship between high blood pressure and brain health (including risk of stroke and dementia), particularly in Black men aged 28 to 45, and provides recommendations to prevent and reduce the impact of high blood pressure on brain health. We offer strategies. This research was funded by NINDS (NS089323, NS095441, NS123507), the Leon Levy Fellowship in Neuroscience, and the Feil Family Foundation.


Source: scitechdaily.com